Viking Therapeutics, Inc.’s $63.25 Million Initial Public Offering

Paul Hastings LLP represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $63.25 million underwritten public offering of common stock.

Viking announced that it intends to use the net proceeds from the financing for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes.

Viking Therapeutics, Inc. operates as a biopharmaceutical company. The Company, led by Brian Lian, Michael Morneau and Amy Broidrick focuses on the development of therapeutics for patients suffering from metabolic and endocrine disorders.

Palo Alto corporate partners Jeff Hartlin (Picture) and Samantha Eldredge led the Paul Hastings team, which also included associate Ed Chu.

Involved fees earner: Jeff Hartlin – Paul Hastings; Samantha Eldredge – Paul Hastings; Edward Chu – Paul Hastings;

Law Firms: Paul Hastings;

Clients: Viking Therapeutics, Inc. ;

Print Friendly, PDF & Email

Author: Ambrogio Visconti